Search the Newsreel

RBC Capital Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $40

RBC Capital has reiterated its Buy rating on Damora Therapeutics (DMRA.US), maintaining a target price of $40. This indicates a continued positive outlook from the firm regarding the company's stock performance.

Damora Therapeutics, Inc. SEC Filing (Aug 10, 2026)

Damora Therapeutics, Inc. (DMRA) filed a post-effective amendment to its S-3 registration statement on August 10, 2026. This amendment follows the company's redomestication from Delaware to the Cayman Islands on July 16, 2026, and clarifies that no new securities are being registered. The filing …

Damora Therapeutics Q2 Results: Net Loss Widens To $31.2 Million

Damora Therapeutics reported a net loss of $31.2 million for Q2 2026, a significant increase from $3.4 million in the prior year, primarily due to soaring R&D expenses for its CLARITY-101 trial. Despite the widening loss, the company boasts strong liquidity with $540.5 million …

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPS

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) announced its quarterly earnings, reporting a loss of $0.39 per share, which surpassed analysts' consensus estimate of a $0.45 loss by $0.06. Following the announcement, shares fell 1.3% to $29.54, resulting in a market capitalization of approximately $1.82 …

Damora Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Damora Therapeutics, Inc. announced its financial results for the second quarter and first six months of 2026, ending June 30th. The company reported a significant increase in net loss for both periods compared to the previous year. For the second quarter, the net loss …

Damora Therapeutics, Inc. Common Stock (DMRA) Earnings Date and Reports 2026

Damora Therapeutics, Inc. Common Stock (DMRA) reported Q2 2026 earnings on August 10, 2026, with an EPS of -$0.39, beating the consensus estimate of -$0.45. The company's earnings are projected to decrease in the next year, from ($2.06) to ($2.14) per share. The article …

Does CLARITY-101’s mutCALR Antibody Launch Change The Bull Case For Damora Therapeutics (DMRA)?

Damora Therapeutics (DMRA) has initiated its Phase 1/1b CLARITY-101 trial for DMR-001, a first-in-class antibody targeting mutant calreticulin in myelofibrosis and essential thrombocythemia. This trial launch de-risks execution and provides a clear catalyst with mid-2027 data, though risks remain due to the company's early-stage, …

Damora Therapeutics, Inc. Common Stock (DMRA) Stock Trends and Sentiment 2026

This page provides an overview of Damora Therapeutics, Inc. Common Stock (DMRA) including its current stock price, trends in media mentions, and page views. It also offers tools and resources for investors to monitor the stock, receive alerts, and conduct further research. The stock …

Damara (DMRA): Lori Firmani plans sale of 1,800 common shares via Maxim

Lori Firmani has filed a notice to sell up to 1,800 shares of Damara (DMRA) common stock through Maxim Group on the NASDAQ, with an aggregate value of $55,980.00 and an anticipated sale date of August 5, 2026. These shares are related to options …

Damora Begins Testing Antibody Designed for Monthly Doses

Damora Therapeutics has initiated a global Phase 1/1b clinical trial (CLARITY-101) for DMR-001, an investigational monoclonal antibody targeting mutant calreticulin (mutCALR) in patients with essential thrombocythemia and myelofibrosis. Preclinical data showed DMR-001 has high binding affinity and a longer half-life, supporting once-monthly subcutaneous dosing. …

Damora Therapeutics, Inc. Common Stock (DMRA) FDA Approvals, PDUFA Dates & Drug Alerts 2026

Damora Therapeutics, Inc. (DMRA) has not received any FDA approvals in the past two years, but its drug DMR-001 is currently under FDA review. The company recently announced the initiation of the global Phase 1/1b CLARITY-101 clinical trial for DMR-001, an investigational monoclonal antibody …

Damora Therapeutics earnings on deck as rare blood cancer race heats up

Damora Therapeutics is set to release its second-quarter earnings, with analysts expecting a loss of 44 cents per share. The pre-revenue biotech is advancing its lead rare blood cancer treatment, DMR-001, towards clinical trials, facing competition from Incyte Corp.'s INCA033989. Investors will focus on …

Ashmore (AMOR) Kembali Perpanjang Buyback Rp7 Miliar hingga Akhir Oktober

Ashmore Indonesia (AMOR) Perpanjang Buyback Saham, Siapkan Dana Rp 7 Miliar

Wedbush Adjusts Damora Therapeutics Price Target to $40 From $35, Maintains Outperform Rating

Wedbush has increased its price target for Damora Therapeutics (DMRA) to $40 from $35, while reiterating an Outperform rating. The company currently holds an average rating of Buy from analysts, with a mean price target of $44.11.

Jefferies Initiates Coverage on Damora Therapeutics With Buy Rating, $50 Price Target

Jefferies has initiated coverage on Damora Therapeutics (DMRA) with a Buy rating and a $50 price target. This new rating is higher than the current average analyst rating of Buy with a mean price target of $44.11 for Damora Therapeutics, according to FactSet.

AMOREPACIFIC Holdings Corp. Revenue Breakdown – KRX:002790

AmorePacific, which plunged 29.88% in the second quarter alone, could rebound significantly if the d..

Amorepacific Incorporates COSRX as a Subsidiary through Additional Stake Acquisition

Amorepacific delivers disappointing Q1 results as China sales slump